用户名:
密 码:
注册
|
忘记密码?
首 页
药品信息
药品检索
全部药品
适应症分类
热门药品
专利信息
专利检索
专利权人导航
专利权人分组导航
分类查询
IPC导航
热门检索
专利分析
概况
申请趋势分析
申请人分析
发明人分析
IPC分析
项目文档
项目
个人项目
文档
个人文档
企业文档
公共文档
标签
互动
特色功能
广州科技订制咨询
特色资讯
医药新闻
帮助中心
关于本软件
药品
文档
专利
新闻
所有专利
选择导航
专利权人导航
专利权人分组导航
分类导航
专利权人导航
NOVARTIS AG [CH](25)
NOVARTIS AG [CH](7)
KAWANAMI TOSHIO [US](3)
KSANDER GARY MICHAEL [US](3)
MOGI MUNETO [US](2)
CONTORNI MARIO [IT](2)
TARLI LORENZO [IT](2)
SKIBINSKI DAVID A G [SG](1)
WU TOM YAO-HSIANG [US](1)
LI YONGKAI [US](1)
专利信息
Translation Company
查询条件
展开筛选条件
[专利权人] 包含 ' NOVARTIS AG [CH]'
清空条件
查询
分析
排序
公开日
公开号
申请日
申请号
中文标题
英文标题
降序
升序
翻到页码
标题
标题2
专利权人
发明人
附图
摘要
摘要2
优先权号
IPC
专利类型
首页
上页
1
2
3
尾页
共
25
条记录, 当前第2/3页。
公开号
公开日
申请号
申请日
1.
US2013178518A1
2013/7/11
US201213716496
2012/12/17
专利标题
:Contact Lenses Containing Carotenoid And Method For Making Same
专利权人
:
NOVARTIS AG [CH]
;
NOVARTIS AG [CH]
;
The instant invention pertains to a method for producing contact lenses with improved oxidative stability of Carotenoids in the contact lens. The method of the invention involves adding a vitamine E material into a contact lens in an amount sufficient to reduce oxidative degradation of Carotenoids in the lens by at least about 30% in comparison with an identical contact lens without the vitamin E material.
2.
US2013171238A1
2013/7/4
US201313734023
2013/1/4
专利标题
:IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA TRACHOMATIS
专利权人
:
NOVARTIS AG [CH]
;
NOVARTIS AG [CH]
;
The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for eliciting a Chlamydia trachomatis specific TH2 immune response. The invention further relates to an immunogenic composition co...
3.
US2013158088A1
2013/6/20
US201113818346
2011/8/22
专利标题
:TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY
专利权人
:
ALBRECHT DIEGO [CH]
;
CHANDRA PRIYAMVADA [US]
;
GODTFREDSEN SVEN [US]
;
JORDAAN PIERRE [CH]
;
LEFKOWITZ MARTIN [US]
;
NOVARTIS AG [CH]
;
The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.
4.
US2013158086A1
2013/6/20
US201213687659
2012/11/28
专利标题
:METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION
专利权人
:
NOVARTIS AG [CH]
;
NOVARTIS AG [CH]
;
The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof
5.
US2013158085A1
2013/6/20
US201213686411
2012/11/27
专利标题
:METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION
专利权人
:
NOVARTIS AG [CH]
;
NOVARTIS AG [CH]
;
The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof
6.
US2013149326A1
2013/6/13
US201313767853
2013/2/14
专利标题
:ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN
专利权人
:
NOVARTIS AG [CH]
;
NOVARTIS AG [CH]
;
Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus ('MenB'). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's ...
7.
US2013137737A1
2013/5/30
US201113813181
2011/8/1
专利标题
:HIGHLY CRYSTALLINE VALSARTAN
专利权人
:
BURGBACHER JENS [CH]
;
HAHN BJOERN THOMAS [DE]
;
RAMPF FLORIAN ANDREAS [FR]
;
SCHNEEBERGER RICARDO [FR]
;
NOVARTIS AG [CH]
;
The present invention describes a highly crystalline form of valsartan, pharmaceutical compositions thereof and process for the preparation thereof.
8.
US2013109729A1
2013/5/2
US201213721521
2012/12/20
专利标题
:PHARMACEUTICAL COMPOSITION
专利权人
:
NOVARTIS AG [CH]
;
NOVARTIS AG [CH]
;
Provided are compositions comprising aqueous solutions of valsartan suitable for oral administration, preferably in pediatric and geriatric populations. Methods for making such compositions and methods for their stabilization are provided.
9.
US2013102594A1
2013/4/25
US201213653738
2012/10/17
专利标题
:Pharmaceutical Formulation of Valsartan
专利权人
:
NOVARTIS AG [CH]
;
NOVARTIS AG [CH]
;
The present invention relates to a pharmaceutical composition in a form of suspension for oral administration comprising valsartan or its pharmaceutically acceptable salts and at least one or two or more of the components selected from glycerol or syrup or the mixture thereof, a preservative, a buffer system and a suspending/stabilizing agent. The present invention further relates to the therapeutic uses of the pharmaceutical composition.
10.
US2013096168A1
2013/4/18
US201213705475
2012/12/5
专利标题
:Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
专利权人
:
IWAKI YUKI [US]
;
KAWANAMI TOSHIO [US]
;
KSANDER GARY MICHAEL [US]
;
MOGI MUNETO [US]
;
NOVARTIS AG [CH]
;
The present invention provides a compound of formula I
首页
上页
1
2
3
尾页
共
25
条记录, 当前第2/3页。
当前查询条件: [专利权人] 包含 ' NOVARTIS AG [CH]'
查询范围
在当前结果中查询
!
专利类型
发明
实用新型
外观设计
!
公开号
CN1234
!
申请号
CN1234
!
专利标题
扩展
PHARMA
!
专利权人
扩展
pfizer
发明人
!
申请日
yyyymmdd
!
公开日
yyyymmdd
优先权号
!
摘要
扩展
PHARMA
IPC
A01B
下载范围
下载第
到
条记录。
下载内容
题录信息
专利全文